Search

2018’s Sjöberg Prize awarded for unique treatment that cures a once fatal cancer

Dr. Zhu Chen, Dr. Anne Dejean and Dr. Hugues de Thé will be awarded the Sjöberg Prize 2018 for their work on how acute promyelocytic leukemia (APL) could be cured based on arsenic and retinoic acid.

Read more

Meet Willem Fibbe, our volunteer of the month

Can you tell us what you do for EHA and when you started?
I have been involved in EHA over a period of twenty years, starting as counselor from 2000-2004.

Read more

Meet Willem Fibbe, our volunteer of the month

Can you tell us what you do for EHA and when you started?
I have been involved in EHA over a period of twenty years, starting as counselor from 2000-2004.

Read more

Get involved

Connect with EHA to develop your skills, share your research, and become part of a vibrant community. EHA is a pioneering European hematology organization with global reach.

Read more

New data exchange platform on rare diseases

The European Commission (EC) launched a new online knowledge-sharing platform – the European Platform on Rare Disease Registration (EU RD Platform) – on February 28, 2019.

Read more

Professor Degos awarded at the 17th Congress of EHA in Amsterdam

Professor Degos has made a major contribution, to our understanding of the pathogenesis and treatment of acute promyelocytic leukemia (APL), to international public health and to the EHA.

Read more

Meet Eva Hellström-Lindberg, our Volunteer of the Month

Can you tell us what you do for EHA and when you started?
These days I am not as involved in EHA as I used to be, besides the various services when asked for, which I think is how it should…

Read more

Meet Eva Hellström-Lindberg, our Volunteer of the Month

Can you tell us what you do for EHA and when you started?
These days I am not as involved in EHA as I used to be, besides the various services when asked for, which I think is how it should…

Read more

Without access to treatment, can we truly innovate in rare diseases?

Interview with Giampaolo Merlini

There have been many developments on rare diseases since the EU Orphan Medicinal Products Regulation came into force in 2000. As the European Commission is evaluating its effectiveness, EHA discussed with Prof.

Read more